PL3539961T3 - Policykliczne pochodne amidowe jako inhibitory CDK9 - Google Patents
Policykliczne pochodne amidowe jako inhibitory CDK9Info
- Publication number
- PL3539961T3 PL3539961T3 PL19165726T PL19165726T PL3539961T3 PL 3539961 T3 PL3539961 T3 PL 3539961T3 PL 19165726 T PL19165726 T PL 19165726T PL 19165726 T PL19165726 T PL 19165726T PL 3539961 T3 PL3539961 T3 PL 3539961T3
- Authority
- PL
- Poland
- Prior art keywords
- amide derivatives
- cdk9 inhibitors
- polycyclic amide
- polycyclic
- cdk9
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185852P | 2015-06-29 | 2015-06-29 | |
| EP19165726.1A EP3539961B1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
| EP16733459.8A EP3313838B1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
| PCT/EP2016/064899 WO2017001354A1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3539961T3 true PL3539961T3 (pl) | 2022-02-14 |
Family
ID=56292699
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16733459T PL3313838T3 (pl) | 2015-06-29 | 2016-06-27 | Policykliczne pochodne amidowe jako inhibitory CDK9 |
| PL19165726T PL3539961T3 (pl) | 2015-06-29 | 2016-06-27 | Policykliczne pochodne amidowe jako inhibitory CDK9 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16733459T PL3313838T3 (pl) | 2015-06-29 | 2016-06-27 | Policykliczne pochodne amidowe jako inhibitory CDK9 |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US9845331B2 (pl) |
| EP (2) | EP3313838B1 (pl) |
| JP (1) | JP6997627B2 (pl) |
| CN (1) | CN107873028B (pl) |
| AR (1) | AR105179A1 (pl) |
| AU (1) | AU2016286200B2 (pl) |
| BR (1) | BR122019013677B1 (pl) |
| CA (1) | CA2989499C (pl) |
| CL (1) | CL2017003306A1 (pl) |
| CO (1) | CO2017013713A2 (pl) |
| CR (2) | CR20210297A (pl) |
| CY (2) | CY1122111T1 (pl) |
| DK (2) | DK3539961T3 (pl) |
| DO (2) | DOP2017000295A (pl) |
| EA (1) | EA035383B1 (pl) |
| ES (2) | ES2902148T3 (pl) |
| HR (2) | HRP20211970T1 (pl) |
| HU (2) | HUE043440T2 (pl) |
| IL (1) | IL256393B (pl) |
| LT (2) | LT3539961T (pl) |
| ME (1) | ME03404B (pl) |
| MX (1) | MX371034B (pl) |
| NI (1) | NI201700174A (pl) |
| PE (1) | PE20180530A1 (pl) |
| PH (1) | PH12017502334A1 (pl) |
| PL (2) | PL3313838T3 (pl) |
| PT (2) | PT3313838T (pl) |
| RS (2) | RS62781B1 (pl) |
| SI (2) | SI3313838T1 (pl) |
| SV (1) | SV2017005598A (pl) |
| TN (1) | TN2017000486A1 (pl) |
| TR (1) | TR201909286T4 (pl) |
| TW (1) | TWI723028B (pl) |
| WO (1) | WO2017001354A1 (pl) |
| ZA (1) | ZA201800563B (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019058348A1 (en) | 2017-09-25 | 2019-03-28 | Astrazeneca Ab | COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER |
| US11319295B2 (en) | 2017-10-09 | 2022-05-03 | Merck Sharp & Dohme Corp. | Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN114786673A (zh) * | 2019-09-11 | 2022-07-22 | 普莱鲁德疗法有限公司 | Cdk抑制剂及其作为药物的用途 |
| US20230219961A1 (en) | 2020-05-12 | 2023-07-13 | Suzhou Alphama Biotechnology Co., Ltd. | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof |
| WO2021227904A1 (zh) | 2020-05-12 | 2021-11-18 | 苏州阿尔脉生物科技有限公司 | 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 |
| WO2021260578A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and cdk9 inhibitor |
| CN115843296B (zh) | 2020-08-07 | 2024-03-08 | 南京迈晟科技有限责任公司 | Cdk9抑制剂及其用途 |
| TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
| CN115381824A (zh) * | 2021-05-24 | 2022-11-25 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN117813289A (zh) * | 2021-07-14 | 2024-04-02 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
| TW202333679A (zh) * | 2021-12-23 | 2023-09-01 | 比利時魯汶大學 | 用於抑制ｙａｐ／ｔａｚ－ｔｅａｄ之四氫吡唑并嘧啶及相關類似物 |
| WO2024039210A1 (ko) | 2022-08-17 | 2024-02-22 | 한국화학연구원 | Cdk2 및/또는 cdk9의 억제 또는 분해용 화합물 및 이들의 의약 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133192A1 (ja) * | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| JP5693951B2 (ja) | 2007-04-24 | 2015-04-01 | アストラゼネカ エービー | プロテインキナーゼの阻害剤 |
| US8507498B2 (en) | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| WO2008129069A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| BRPI0818543A2 (pt) | 2007-10-12 | 2018-10-23 | Ingenium Pharmaceuticals Gmbh | inibidores de proteína cinase |
| MX2012002752A (es) | 2009-09-04 | 2012-04-19 | Novartis Ag | Compuestos de heteroarilo como inhibidores de cinasa. |
| US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
| GB201002911D0 (en) * | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| WO2011110612A1 (en) | 2010-03-10 | 2011-09-15 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| AR081810A1 (es) * | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| WO2012101063A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| CN103339110A (zh) * | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 |
| UA114410C2 (uk) * | 2011-10-06 | 2017-06-12 | Байєр Інтеллектуал Проперті Гмбх | Гетероциклілпіри(mi)динілпіразол |
| BR112015021549A2 (pt) * | 2013-03-13 | 2017-07-18 | Abbvie Inc | inibidores de piridina cinase cdk9 |
| AU2014244263A1 (en) | 2013-03-13 | 2015-08-13 | Abbvie Inc. | CDK9 kinase inhibitors |
| WO2014151444A1 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
| JP2016512560A (ja) | 2013-03-14 | 2016-04-28 | アッヴィ・インコーポレイテッド | ピロロピリミジン系ｃｄｋ９キナーゼ阻害薬 |
-
2016
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en active Application Filing
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-15 PH PH12017502334A patent/PH12017502334A1/en unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-04-19 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03740B (me) | Jedinjenja indol karboksamida korisna kao inhibitori kinaze | |
| ZA201800563B (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| IL266745A (en) | Benzodiazolonium compounds as enac inhibitors | |
| HK1257565A1 (zh) | 作為htra1抑制劑的新型三氟甲基丙酰胺衍生物 | |
| HK1257567A1 (zh) | 作為htra1抑制劑的新型二氟酮酰胺衍生物 | |
| HK1253572A1 (zh) | 作為tnap抑制劑的吡啶並噁嗪酮化合物 | |
| IL258438B (en) | 2-Aminoquinoline derivatives as p70s6 kinase inhibitors | |
| HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 |